Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Adis, Springer Healthcare
2025-01-01
|
| Reeks: | Drugs - Real World Outcomes |
| Online toegang: | https://doi.org/10.1007/s40801-024-00477-4 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|